A phase 2 study of AMG 479 in relapsed or refractory Ewing's family tumor and desmoplastic small round cell tumors.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Ganitumab (Primary)
- Indications Ewing's sarcoma; Primitive neuroectodermal tumours; Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Amgen; NantCell
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 03 Jun 2010 Planned end date changed from 1 May 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.